Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02860806
Recruitment Status : Completed
First Posted : August 9, 2016
Last Update Posted : January 30, 2018
Sponsor:
Information provided by (Responsible Party):
Janssen-Cilag International NV

Brief Summary:
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of single escalating intravenous (IV) doses of JNJ-63623872 administered as a continuous infusion; to evaluate the safety and tolerability of single escalating IV doses of JNJ-63623872 administered as a continuous infusion; to characterize the single-dose PK of JNJ-63623872 of one selected dose administered as a continuous IV infusion at various durations and to characterize the single- and repeat-dose PK of JNJ-63623872 administered as a continuous infusion.

Condition or disease Intervention/treatment Phase
Healthy Drug: JNJ-63623872 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Absolute Bioavailability of JNJ-63623872 Administered as an Intravenous Infusion and a 600-mg Oral Dose in Healthy Adult Subjects
Actual Study Start Date : August 8, 2016
Actual Primary Completion Date : June 6, 2017
Actual Study Completion Date : June 10, 2017

Arm Intervention/treatment
Experimental: Part 1: Period 1 (JNJ-63623872 100 mg or Placebo)
Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) [3 milligram per milliliters (mg/mL) solution] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Drug: Placebo
Intravenous infusion of matching placebo.

Experimental: Part 1: Period 2 (JNJ-63623872 200 mg or Placebo)
Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Drug: Placebo
Intravenous infusion of matching placebo.

Experimental: Part 1: Period 3 (JNJ-63623872 300 mg or Placebo)
Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Drug: Placebo
Intravenous infusion of matching placebo.

Experimental: Part 2: Group 1 (EFG)
Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G). Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Experimental: Part 2: Group 2 (FGE)
Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Experimental: Part 2: Group 3 (GEF)
Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Experimental: Part 2: Group 4 (GFE)
Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Experimental: Part 2: Group 5 (FEG)
Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Experimental: Part 2: Group 6 (EGF)
Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Experimental: Part 3: JNJ-63623872 300 mg
Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10. Duration of infusion and dose will be selected after Part 2 of this study is completed.
Drug: JNJ-63623872
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.




Primary Outcome Measures :
  1. Maximum Observed Analyte Concentration (Cmax) [ Time Frame: Up to 10 days ]
    The Cmax is the maximum observed analyte concentration.

  2. Fluctuation Index (FI) [ Time Frame: Up to 10 days ]
    FI is defined as the percentage fluctuation between the Ctrough, morning analyte concentration and the maximum analyte concentration.

  3. Average Analyte Concentration (Cavg) [ Time Frame: Up to 10 days ]
    The Cavg is an average analyte concentration at steady-state over the dosing interval.

  4. Time to Reach the Maximum Observed Analyte Concentration (Tmax) [ Time Frame: Up to 10 days ]
    The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

  5. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to 12 Hour (AUC [0-12]) [ Time Frame: Up to 10 days ]
    The (AUC [0-12]) is the area under the plasma concentration-time curve from time 0 to 12 hour post dose, calculated by linear-linear trapezoidal summation.

  6. Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC [0-last]) [ Time Frame: Up to 10 days ]
    The (AUC [0-last]) is the area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable (non-below quantification limit [non-BQL]) concentration, calculated by linear-linear trapezoidal summation.

  7. Area Under the Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) [ Time Frame: Up to 10 days ]
    The AUC (0-infinity) is the area under the plasma concentration-time curve from time 0 to infinity, calculated as the sum of AUC(last) and C(last)/lambda(z), where Clast is the last observed measurable (non-BQL) concentration; extrapolations of more than 20.00 percent (%) of the total AUC are reported as approximations.

  8. Elimination Rate Constant (Lambda[z]) [ Time Frame: Up to 10 days ]
    Lambda(z) is apparent terminal elimination rate constant, determined by linear regression using the terminal log-linear phase of the log transformed concentration-time curve.

  9. Apparent Terminal Elimination Half-life (t1/2term) [ Time Frame: Up to 10 days ]
    Apparent terminal elimination half-life is defined as 0.693/Lambda[z].

  10. Systemic Clearance (CL) [ Time Frame: Up to 10 days ]
    CL is the total systemic clearance, following intravenous administration.

  11. Apparent Clearance (CL/F) [ Time Frame: Up to 10 days ]
    CL/F is the total apparent clearance, following extravascular administration.

  12. Volume of Distribution (Vd) [ Time Frame: Up to 10 days ]
    The Vd is defined as volume of distribution, following single dose intravenous administration.

  13. Apparent Volume of Distribution (Vd/F) [ Time Frame: Up to 10 days ]
    Vd/F is defined as apparent volume of distribution, following single dose extravascular administration.

  14. Volume of Distribution at Steady-State (Vss) [ Time Frame: Up to 10 days ]
    Vss is defined as apparent volume of distribution at steady-state following intravenous administration.

  15. Observed Accumulation Index (RA abs) [ Time Frame: Up to 10 days ]
    Observed Accumulation Index is calculated by AUC12h, steady state/(AUC12h, single dose).

  16. Morning Trough Analyte Concentration (Ctrough, morning) [ Time Frame: Up to 10 days ]
    Ctrough, morning is defined as observed analyte concentration just prior to the beginning of a dosing interval.

  17. Evening Trough Analyte Concentration (Ctrough, evening) [ Time Frame: Up to 10 days ]
    Ctrough, evening is defined as observed analyte concentration at the end of a dosing interval.

  18. Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability [ Time Frame: Up to End of Study (Day 14) ]

Secondary Outcome Measures :
  1. Absolute Bioavailability (F[abs]) [ Time Frame: Up to 10 days ]
    The F(abs) is calculated as AUC (0-infinity), oral/ AUC (0-infinity), intravenous (iv)*Dose, iv/Dose, oral*100 %, where AUC (0-infinity) is area under the concentration-time curve from time zero to extrapolated infinite time, and D is the dose of administered drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A female participant (except if postmenopausal) must have a negative serum beta- human chorionic gonadotropin (beta-hCG) pregnancy test at screening and on Day -1 of each treatment period
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 90 days after discontinuation of study drug
  • During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug, in addition to the highly effective method of contraception in the female partner, a man regardless of having been vasectomized: 1) who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (example, condom with spermicidal foam/gel/film/cream/suppository), 2) must agree not to donate sperm and 3) who is sexually active with a pregnant women must use a condom
  • Must have a Body Mass Index (BMI); weight kilogram [kg]/height^2 [m]^2) between 18.0 and 30.0 kilogram per meter square (kg/m^2) (extremes included) at Screening
  • Must have a blood pressure (supine after at least 5 minutes rest and standing after at least 1 minute standing) between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic at Screening

Exclusion Criteria:

  • Has a history of current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • With a past history of heart arrhythmias (extrasystoli, tachycardia at rest), history of risk factors for Torsade de Pointes syndrome (example, hypokalemia, family history of long QT Syndrome)
  • Has known allergies, hypersensitivity, or intolerance to JNJ-63623872 or its excipients
  • With any history of clinically significant skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, food allergy, or urticaria
  • With a history of clinically significant drug allergy such as, but not limited to, sulfonamides and penicillins, or drug allergy diagnosed in previous studies with experimental drugs
  • Has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening
  • Has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02860806


Locations
Layout table for location information
Belgium
Merksem, Belgium
Sponsors and Collaborators
Janssen-Cilag International NV
Investigators
Layout table for investigator information
Study Director: Janssen-Cilag International NV Clinical Trial Janssen-Cilag International NV
Layout table for additonal information
Responsible Party: Janssen-Cilag International NV
ClinicalTrials.gov Identifier: NCT02860806    
Other Study ID Numbers: CR108196
63623872FLZ1002 ( Other Identifier: Janssen-Cilag International NV )
2016-000921-37 ( EudraCT Number )
First Posted: August 9, 2016    Key Record Dates
Last Update Posted: January 30, 2018
Last Verified: January 2018

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No